outperform
initi coverag veru outperform rate price target
revenu meaning offset burn near-term product opportun
risk-mitig high-margin offer signific upsid prospect
new chemic entiti unmet need prostat cancer believ data
readout zuclomiphen phase manag hot flash prostat
cancer patient receiv androgen-depriv therapi first-
in-class oral anti-tubulin phase zytiga/xtandi-resist metastat prostat
cancer catalyz investor attent off-the-radar name
toward mix small-molecul drug candid novel repurposed/
reformul benefit on-going revenu stream consum health
product sale togeth lean cost-effici structur oper cash need
intern met least
tadfin expect approv tadalafil/finasterid combin tablet
effect bph finasterid alon address common co-
morbid ed mani patient alreadi take separ tablet togeth
sale may reach given gener compon distribution-onli
model make attract margin
zuclomiphen expect estrogen receptor agonist success
develop treat hot flash reportedli bothersom symptom
anti-androgen therapi drive non-compli phase data
enabl go-forward dose select potenti phase entri
extens human safeti experi yet patent protect see
disrupt microtubul distinct fashion exist tubulin
agent taxan vinca anim safeti appear less oner oral
bioavail impress pre-clin efficaci sever highli refractori
tumor type could fill gap androgen super-block
chemo phase data report
financi manag commerci segment net revenu
y/i gm yield oper loss despit pipelin
 activ ceo/founder/form academ urologist mitchel steiner led
inc focus prostat cancer treatment support care
year price histori veru
veru inc oncolog urolog
commerci novel medicin
prostat cancer continuum care
urolog specialti pharmaceut
analyst certif import disclosur see disclosur
commerci revenu meaning offset burn near-term
product opportun risk-mitig high-margin offer
signific upsid prospect new chemic entiti unmet need
prostat cancer believ data readout
phase manag hot flash prostat cancer patient
receiv androgen-depriv therapi first-in-
class oral anti-tubulin phase chemo-nav zytiga/xtandi-
resist metastat prostat cancer catalyz investor attent
zuclomiphen tadfin obtain fda approv
zuclomiphen tadfin gener peak sale
respect
zuclomiphen price
data phase hot flash
initi phase data advanc prostat cancer
submit nda tadfin
potenti start phase hot flash
zuclomiphen gener peak sale higher
tadfin gener peak sale higher
zuclomiphen price higher
show clinic promis prostat cancer highli refractori
anti-androgen therapi
zuclomiphen and/or tadfin fail obtain fda approv
zuclomiphen gener peak sale lower
tadfin gener peak sale lower
zuclomiphen price lower
valu veru per share use risk-adjust discount cash flow analysi valuat obtain assign likelihood fda
approv zuclomiphen tadfin respect forecast risk-unadjust peak sale zuclomiphen tadfin
respect assumpt includ wacc termin valu launch price zuclomiphen gross margin zuclomiphen
tadfin valu rest pipelin
risk includ failur zuclomiphen and/or tadfin obtain fda approv unexpect industri competit regulatori
surpris could add delay increas risk approv need build sales/distribut infrastructur addit capit requir
obtain approv achiev profit
note view veru stock trade specul appropri risk-toler investor
revenu meaning offset burn near-term product opportun
risk-mitig high-margin offer signific upsid prospect
new chemic entiti unmet need prostat cancer believ
data readout zuclomiphen phase manag hot flash
prostat cancer patient receiv androgen-depriv therapi
first-in-class oral anti-tubulin phase chemo-nav zytiga/xtandi-
resist metastat prostat cancer catalyz investor attent off-the-
zuclomiphen estrogen receptor agonist develop treat hot
flash men prostat cancer receiv us indic
lack approv therapi current option inadequ hot flash
reportedli bothersom symptom anti-androgen therapi major
driver non-compli note effect result long-term
lack estrogen bodi make testosteron loss bone
miner densiti meaning contribut morbidity/mort despit improv
cancer-rel outcom therapeut option grown zuclomiphen
substanti record human exposur part mixtur approv sinc
develop fda pathway new chemic entiti
zuclomiphen protect least method-of-us patent look
forward phase data adt-rel hot flash summer
demonstr efficaci signal also enabl dose select phase test
could begin earli see us sale potenti
zuclomiphen potenti launch
novel oral avail small-molecul bind alpha
beta tubulin henc disrupt microtubul uniqu exist chemotherapi
 taxan vinca alkaloid also appear caus less neutropenia
neurotox pre-clin set demonstr impress
efficaci model prostat cancer refractori hormon agent well
taxan phase trial patient refractori newer anti-androgen
zytiga xtandi on-going look forward see initi phase data reveal
sign clinic efficaci may caus investor assign greater
valu candid anti-tumor activ seen challeng tumor triple-
neg breast cancer platinum-refractori ovarian cancer suggest drug
may therapeut potenti multipl oncolog indic
veru nearest-term new product opportun tadfin combin tablet
consist tadalafil lli ciali approv bph ed finasterid
mrk proscar approv bph could begin gener revenu
bph affect male popul drug bph repres
commonly-prescrib medic us mani men alreadi take
two medic togeth shown combin
effect bph finasterid alon addit product help ed
common problem older men veru expect minim commerci spend
plan sell via distribut partner tadfin demonstr bioequival
compon taken separ henc elig approv via
fda pathway nda submit later year
finasterid tadalafil avail gener believ tadfin could
achiev us sale high margin grant patient applic would
protect tadfin formul
valu veru per share use risk-adjust discount cash flow analysi
valuat obtain assign likelihood fda approv
zuclomiphen tadfin respect forecast peak sale
zuclomiphen tadfin respect assumpt
includ wacc termin valu launch price zuclomiphen
margin zuclomiphen tadfin valu rest pipelin
exhibit probabl success
exhibit part
veru inc veru revenue-gener clinical-stag pharmaceut compani
commit develop novel product men health focu
prostat cancer treatment support care develop pipelin featur
candid treatment benign prostat hypertrophi file nda tadfin
late manag hot flash men treat
androgen-depriv therapi prostat cancer zuclomiphen phase data
report treatment castration-resist prostat cancer
phase highli androgen-refractory/chemo-elig set
commerci busi gener revenu sale femal condom
roman swipe benzocain wipe prematur ejacul
productindicationev timingimpact begin without edsubmit flash veru
tadalafil inhibitor approv bph ed finasterid type
alpha reductas inhibitor approv bph lower dose male pattern hair
loss pre-ind meet fda confirm tadfin qualifi
pathway agre could base upon singl
bioequival studi note drug-drug interact co-administr
studi alreadi complet
symptomat bph believ affect male popul approv
medic wide prescrib co-administr tadalafil finasterid
fda-approv symptomat treatment intern random double-
blind daily-dos studi men tadalafil finasterid shown
effect finasterid alon six month bph also provid ed
benefit safeti unremark
exhibit finasterid without tadalafil bph
anoth compar studi combo shown improv overal sexual
satisfact ed even men without ed seen finasterid alon
veru bioavailability/bioequival studi single-dos random two-
period crossov studi healthi male year old result show
tadfin tadalafil cmax less tadalafil alon veru current
await six-month stabil data gmp commerci batch plan submit
nda late follow upcom pre-nda meet anticip approv
launch would fall
per expect label tadfin target market would men bph due
enlarg prostat cc other might benefit would would
get suffici benefit either agent alon alpha-block tamsulosin
monotherapi exist combin class alpha-
veru plan commerci tadfin via telemedicin channel primari
care segment licens us ex-u right urolog specialti
pharmaceut compani neglig spend sale market
veru benefit margin model peak us sale dose
finasterid dose approved/us bph prescrib us
symphoni data sale estim would impli current finasterid
bph market move tadfin
veru patent applic tadfin formul would offer protect
issu
prostat cancer treatment
prostat cancer second lead caus death men new
us case expect american cancer societi estim us
preval prostat cancer million case
report incid prostat cancer declin sinc
peak partli attribut decreas prostate-specif antigen
screen follow prevent servic task forc uspstf
recommend updat mortal rate diseas also
declin aid advanc treatment despit declin
epidemiologist express concern pool undiagnos patient could
begin revers mortal rate declin within next year
diagnos treat albeit rel late stage diseas
treatment surgeri radiat recommend local advanc prostat
cancer cure often achiev diseas detect initi stage
nonetheless patient relaps prognosi patient
testosteron androgen stimul prostat cancer growth metastasi
hormon made primarili test small fraction made
adren gland gonadotropin-releas hormon gnrh produc
hypothalamu stimul releas lutein hormon lh follicle-stimul
hormon fsh pituitari gland men lh fsh turn stimul
synthesi secret testicular androgen
patient symptomat metastat diseas usual treat androgen-
depriv therapi use gnrh agonist abbvi lupron
gener avail dramat reduc testosteron androgen
near-castr level estim patient gnrh agonist
us estim approxim patient diagnos prostat
cancer receiv within six month diagnosi therapi may
effect control diseas sever year nearli case prostat
cancer eventu develop resist hormon suppress therapi
castrate-resist prostat cancer refer tumor progress
annual us treatment usual involv addit non-steroid
anti-androgen bicalutamid azn casodex gener avail
block androgen receptor recent second-gener compound consist
jnj structur analog xtandi enzalutamid approv erleada
apalutamid approv potent offer safeti advantag
less hepatotox expens on-brand jnj zytiga
approv gener avail sinc inhibitor block
adren androgen product also use stage
continu progress patient may becom elig anti-mitot
chemotherapi standard care anti-tubulin docetaxel sni taxoter
gener avail provid two- three-month median surviv benefit
recent approv cabazitaxel sni jevtana option docetaxel
failur well topoisomeras inhibitor mitoxantron
critic compon prostat cancer manag caus advers
gynecomastia erectil dysfunct time osteoporosi metabol
syndrom includ weight gain stem low estrogen state
associ occur circul male estrogen
made testosteron
effect withdraw estrogen caus hypothalam deregul
decreas circul endorphin catecholamin blood vessel dilat
respons lead increas serotonin norepinephrin releas
lower thermoregulatori set point condit subtl chang bodi
temperatur trigger heat loss mechan perceiv hot flash addit
sudden sensat heat often profus perspir occasion
palpit chill shiver feel anxieti
hot flash perceiv patient troublesom side effect
patient androgen depriv therapi experi hot
flash report troublesom side effect one
studi patient said hot flash interf sleep report
interf abil enjoy life also common caus
non-compli improv spontan patient
continu experi symptom long receiv
life-long palli set sever year adjuv set
report men continu report hot flash five year
still flash eight year
exhibit publish trial incid hot flash men treat prostat cancer
exhibit toxic grade proport patient hot flash
hot flash poorli manag current option
therapi approv treat hot flash varieti
agent evalu hot flash women either post-
menopaus receiv hormon therapi breast cancer rel
trial conduct men
drug use off-label address adt-induc hot flash men consist primarili
ssri paroxetin ssnri venlafaxin megestrol acet
megac synthet progestin paroxetin approv hot flash women
label indic
pilot trial shown ssri reduc incid hot flash
men prostat cancer experienc event random
double-blind trial compar efficaci venlafaxin
medroxyprogesteron acet progestin cyproteron acet
anti-androgen/progestin men receiv lhrh analogu
prostat cancer conclud three effect reduc hot flash
six month treatment hormon treatment significantli
effect ssri venlafaxin across studi non-hormon agent tend
less efficaci hormon therapi treatment hot flash
despit efficaci class medic provid use
meaning limit poor toler gi symptom serotonerg
agent increas cardiovascular risk includ rate
thromboembol weight gain steroid gabapentin sometim
use drowsi dizzi common issu estradiol use
past treat symptom poor oral bioavail result
inconsist dose often accompani breast swelling/tend
increas cardiovascular risk would predict chronic use
veru develop zuclomiphen adt-rel hot flash
veru develop oral non-steroid select estrogen receptor modul
serm known zuclomiphen manag hot flash men
prostat cancer zuclomiphen one two geometr isom
enclomiphen drug clomiphen clomid drug approv sinc
stimul ovul anovulatori women desir pregnanc zuclomiphen
occur mixtur clomiphen
clomid wide use women last five decad also
receiv off-label use men commonli treatment male infertil due
low testosteron enclomiphen isom anti-estrogen clomid
increas testicular product androgen stimul pituitari
secret lh/fsh believ us men use clomid
infertil hypogonad fda brief document decemb addit
number publish studi clomiphen total men
dose high mg/day three year use altogeth
substanti record safeti zuclomiphen men
singl isom zuclomiphen shown
work ident estrogen restor uterin weight ovariectom
surpass estrogen stimul uterin epitheli height
activ estrogen cell model
result testicular degener male mice key indic estrogen
result lower testosteron castrat level estrogen
despit zuclomiphen approv part clomid mani year
never approv singl isom therefor fda regard
entir new drug zuclomiphen develop nda
clomid list hot flash side effect due enclomiphen anti-estrogen
activ good option treat side effect
top-lin data zuclomiphen phase trial expect
follow ind submiss zuclomiphen taken directli random
double-blind placebo-control phase trial began septemb
four-arm trial evalu daili dose zuclomiphen
placebo men advanc prostat cancer
experi moderate-to-sever hot flash sever definit hot flash
follow mild sensat heat without sweat moder sensat heat
sweat abl continu activ sever sensat heat sweat
caus cessat activ trial conduct site
particip continu receiv throughout first primari endpoint
mean chang frequenc moderate-to-sever hot flash week four
second primari analysi week trial power show
improv vs placebo literatur indic placebo effect veru also
collect data bone turnov marker relev measur sinc lead
progress bone miner densiti loss eventu increas fractur risk
top-lin result trial expect veru
expect select go-forward dose enter pivot program consist
two phase trial similar design recruit total patient
expect registr program begin earli
phase data predict futur develop prospect fda
regard frequenc sever hot flash approv endpoint per
guidanc recent exampl bijuva approv octob
treatment moderate-to-sever hot flash post-menopaus women
frequenc sever week vs placebo co-primari endpoint
sale potenti zuclomiphen us
estim us men one-third treat prostat
cancer popul number like increas given newer
power hormon option enabl men prostat cancer remain
longer period base literatur estim believ affect
hot flash rate moder sever therefor
popul would target candid zuclomiphen therapi
assum annual price impli market opportun
zuclomiphen protect us method-of-us patent expir
veru also recent file patent applic seek protect zuclomiphen
composit matter base polymorph identifi character
despit abil recent androgen block agent extend hormon
therapi castration-resist prostat cancer eventu progress norm
grow segment men progress zytiga xtandi erleada
typic offer chemotherapi drug docetaxel cabazitaxel
interfer cell divis interact tubulin protein alpha- beta-
tubulin polymer within cell form microtubul element mitot spindl
allow cell divid
taxan avail iv administr carri signific safeti risk
hypersensit neutropenia neurotox resist drug
result part due substrat p-glycoprotein multi-drug
transport use cancer cell defend cytotox
first-in-class oral avail anti-tubulin bind alpha
beta tubulin unlik anti-tubulin drug substrat p-glycoprotein
bind site distinct use taxan vinca alkaloid
similar tubulin-destabil agent arrest cell cycl
transit lead apoptosi also shown abil
cleav parp protein anoth valid target anti-cancer therapi
shown exert potent anti-tumor activ pre-clin prostat
cancer model resist enzalutamid abirateron taxan
compound also demonstr compel activ challeng tumor
model includ pancreat triple-neg breast ovarian
exhibit inhibit growth taxane-resist prostat cancer
exhibit activ enzalutamide/abiraterone-resist prostat cancer model
pre-clin data demonstr anti-canc activ refractori tumor
model report abstract form februari gu meet
well european associ urolog congress held march
barcelona spain addit data present aua meet may
develop advanc prostat cancer
refractori newer anti-androgen
veru recent enter phase trial castration-resist prostat
cancer patient refractori enzalutamid abirateron may
treat one cours docetaxel studi conduct five us
current phase portion enrol patient dose-escal accord
design phase portion expect enrol patient
primari endpoint reduct veru expect announc result full
phase popul plan releas interim data
protect us composition-of-matt patent expir
elig five year term extens patent applic file
sni taxoter approv first-lin chemotherapi
docetaxel typic dose everi three week one-hour intraven infus
continu oral prednison mg bid trial docetaxel
demonstr month median overal surviv vs month
mitoxantron compar docetaxel black-box warn
neutropenia liver toxic docetaxel associ anemia
grade neutropenia grade nausea diarrhea
fatigu commonli experienc docetaxel limit therapi
sni jevtana approv taxotere-refractori cprc
cabazitaxel indic mcrpc previous treat docetaxel
month mitoxantron cabazitaxel black-box warn
exhibit takeout comp prostat cancer
exhibit ww sale mm newer prostat cancer drug
femal condom fda-approv product femal use
protect pregnanc well sti manufactur malaysian plant
annual capac unit
commerci veru femal health compani divis
market varieti entiti includ ministri health govern health
agenc un agenc nonprofit organ commerci partner public
sector repres revenu custom includ unfpa usaid brazil
south africa
public sector base revenu august veru
award south african tender provid annual revenu
next three year decemb veru award
brazilian tender specifi unit
veru work expand high-margin us prescript market
work major distributor anda cardin
support broad pharmaci avail
roman swipe formerli preboost medic individu wipe use
desensit male genitalia prevent prematur ejacul veru
sign multi-year exclus us suppli distribut agreement roman
health ventur premier fast-grow men health telemedicin
compani discret sell men health product via internet minimum
requir call roman health ventur purchas million unit per year
mitchel steiner md fac serv presid chief execut offic
compani director sinc octob dr steiner co-
founder aspen park serv aspen park chief execut offic
presid vice chairman board juli octob
dr steiner consult presid urolog
member senior manag inc respons
launch market sale reimburs prostat cancer test
urologist primari care physician dr steiner also co-found
inc men health oncolog public compani serv chief
execut offic vice chairman board director
dr steiner board certifi urologist fellow american colleg
surgeon held numer academ appoint includ assist
professor urolog cell biolog patholog vanderbilt school medicin
chairman professor urolog director urolog
oncolog research chair excel urolog oncolog
univers tennesse dr steiner hold ba molecular
biolog chemistri vanderbilt univers md univers
tennesse perform surgic urolog train john hopkin
hospit postdoctor research fellow cell biolog vanderbilt school
medicin
harri fisch md fac serv director compani sinc octob
dr fisch co-found aspen park serv chairman
board chief scientif offic aspen park juli octob
dr fisch serv chief execut offic
presid millennium scienc inc dr fisch also numer academ
clinic appoint includ clinic professor urolog reproduct
medicin weill colleg medicin cornel univers
director male reproduct center albert einstein colleg
medicine/montefior medic center professor clinic
urolog columbia univers colleg physician surgeon
dr fisch host dr harri fisch show men
howard stern siriusxm radio channel dr fisch board certifi
urologist fellow american colleg surgeon dr fisch hold ba
chemistri state univers new york binghamton md mount
sinai school medicin new york perform surgic urolog train
albert einstein colleg medicine/montefior medic center
philip kuhn evp strategi commerci
mr kuhn join veru januari respons lead compani
licens strategi execut mr kuhn year experi commerci
strategi work lead biolog diagnost devic manufactur
prepar well lead veru strategi effort mr kuhn career
opportun lead sale market strategi activ global
basi number firm includ abbott johnson johnson boston scientif
smith nephew orthofix recent isto biolog prior join
compani mr kuhn serv chief commerci offic isto biolog
engin success turnaround sale commerci busi
privat equiti earlier career mr kuhn held senior role global vice
presid market orthofix smith nephew addit mr kuhn held
role director market peripher vascular stent director market
compani file opco research
compani file opco research
compani file opco research
mm except per share data fy sexual total y/i growth gross gross margin advertis sg loss settlement ar- busi acquisition- total oper oper oper incom expens pre-tax incom pre-tax incom expens tax rate stock dividend- net incom sale dilut gaap y/i share y/i except per share data fy flow net cash use net cash use financing- net chang equival equival equiv incl restrict total current total total current total common addit paid-in accumul comprehens loss accumul treasuri stock total sharehold total liabil sharehold veru outperform
stock price compani mention report
co lly-nys cover
